Ultragenyx Pharmaceutical Inc. Class Action: Levi & Korsinsky Reminds Ultragenyx Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 6, 2026 - RARE [Accessibility Statement] Skip NavigationNEW YORK, Feb. 18, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or the "Company") (NASDAQ: RARE) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Ultragenyx investors wh ...

On CNBC's “Halftime Report Final Trades,” Joshua Brown, co-founder and CEO of Ritholtz Wealth Management, said he remains long on Apple Inc. (NASDAQ:AAPL) .Supporting his view, Wedbush analyst Dan Ives, on Tuesday, reiterated Apple with an Outperform rating and maintained a $350 price target.Jim Lebenthal, partner at Cerity Partners, said AstraZeneca PLC (NYSE:AZN) is a high-quality pharmaceutical stock.On the earnings front, AstraZeneca, on Feb. 10, reported fourth-quarter 2025 sales of $15.50 billion, up ...

Core Viewpoint - Tarsus Pharmaceuticals has appointed David E. I. Pyott, a prominent figure in the biopharmaceutical industry and former CEO of Allergan, to its Board of Directors, which is expected to enhance the company's growth and innovation in eye care and other therapeutic areas [1][2][10]. Company Overview - Tarsus Pharmaceuticals focuses on revolutionizing treatment for patients, particularly in eye care, and is advancing its pipeline to address diseases with high unmet needs across various therapeutic categories, including dermatology and infectious disease prevention [5]. Leadership Experience - David E. I. Pyott has over 17 years of experience as CEO of Allergan, where he grew the company from approximately $1 billion in sales to over $7 billion in revenue, demonstrating a strong ability to navigate market complexities while maintaining a focus on long-term growth [2][3]. - Pyott has also held significant roles at Novartis and has been recognized as one of Harvard Business Review's "100 Best Performing CEOs in the World" [2]. Strategic Vision - Pyott expressed enthusiasm about joining Tarsus at a pivotal time, highlighting the company's strong foundation with its lead product and promising pipeline, and his commitment to building long-term value and advancing innovation in eye care [3]. Current Developments - Tarsus's lead commercial product, XDEMVY (lotilaner ophthalmic solution) 0.25%, is FDA approved for treating Demodex blepharitis, and the company is also developing additional treatments, including TP-04 for ocular rosacea and TP-05 for Lyme disease prevention, both currently in Phase 2 trials [5].

Core Insights - Eli Lilly and Company (LLY) is a leader in the diabetes and obesity treatment market, driven by the success of its GLP-1 therapies, Mounjaro and Zepbound, which utilize tirzepatide for effective treatment [1][2] Industry Overview - The global obesity drug market is expected to grow significantly, reaching nearly $95 billion by 2030 and potentially $125 billion by 2035, according to Goldman Sachs estimates [3] - Both Lilly and Novo Nordisk are competing to develop next-generation GLP-1 treatments, including oral options, to maintain their market leadership [3] Product Pipeline - Lilly is investing in obesity treatments with several new molecules in clinical development, including oral and injectable medications [4] - A key candidate in Lilly's obesity pipeline is orforglipron, a once-daily oral GLP-1 small molecule, which could lower treatment burden and broaden patient adoption [5] - Positive data from six studies on orforglipron has led to regulatory applications in the U.S., EU, and other countries, with a U.S. launch expected in Q2 2026 [6][11] - Lilly is also evaluating orforglipron in late-stage studies for other conditions, expanding its revenue potential beyond obesity and type II diabetes [7] - Another candidate, retatrutide, is being studied for obesity and knee osteoarthritis pain, with plans for approval in 2026 [8][9] Competitive Landscape - Competition in the obesity market is intensifying, with Novo Nordisk set to launch an oral version of Wegovy in January 2026, potentially impacting Lilly's market share [12] - Smaller biotech companies are also developing oral GLP-1 drugs, such as Viking Therapeutics and Structure Therapeutics, which may further increase competition [13][14] Financial Performance - Lilly's stock has increased by 19.5% over the past year, compared to the industry's 18.2% rise [15] - The stock is currently trading at a price/earnings ratio of 29.70, higher than the industry average of 18.82, but below its 5-year mean of 34.57 [17] - The Zacks Consensus Estimate for 2026 has risen from $33.15 to $33.80 per share, indicating positive revisions in earnings expectations [20]

Preliminary blinded CR rate showed 67% improvement over historical cytarabine response Roughly 35% of the subjects treated to date represent ventoclax regimen failuresFirst 45 subjects treated on track for Q1 2026 milestone with unblinding thereafter; treated 35 subjects to date with another 11 identified Continued absence of cardiotoxicity and high efficacy expected to position Annamycin as a “significant advancement” in AML treatment HOUSTON, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nas ...

The US Food and Drug Administration will review a Moderna flu shot made with mRNA technology, reversing a previous decision that shocked Wall Street and spurred a public verbal dispute between the company and its regulator https://t.co/kO9TK4BTAK ...

Core Insights - The price-to-book (P/B) ratio is a key metric for evaluating stock value, calculated by dividing the stock's current price by its book value per share [1][2] - The P/B ratio is gaining traction as a tool for identifying low-priced stocks with high-growth potential, alongside traditional metrics like price-to-earnings (P/E) and price-to-sales (P/S) [2][3] Understanding Book Value - Book value represents the total value remaining for shareholders if a company were to liquidate its assets after settling all liabilities [4] - It is calculated by subtracting total liabilities from total assets, often equating to common stockholders' equity [5] P/B Ratio Analysis - A P/B ratio of less than one indicates that a stock is undervalued, while a ratio greater than one suggests it may be overvalued [6][7] - The P/B ratio should be compared within industries for more accurate assessments [6] - Limitations exist for the P/B ratio, particularly for companies with significant R&D expenditures or high debt levels [9] Investment Opportunities - Five stocks identified with low P/B ratios and strong growth prospects include AES Corporation, Harmony Biosciences, Concentrix, Patria Investments Limited, and Global Payments [3][10] - AES has a projected 3-5 year EPS growth of 11.2% and a Value Score of A [10][16] - Harmony Biosciences boasts a Zacks Rank of 1 and a projected EPS growth of 27.11% [10][17] - Concentrix has a projected EPS growth of 8.76% and a Value Score of A [17] - Patria Investments Limited has a projected EPS growth of 15.76% and a Zacks Rank of 2 [18] - Global Payments has a projected EPS growth of 11.54% and a Zacks Rank of 2 [19]

Core Viewpoint - Allarity Therapeutics has initiated a Phase 2 clinical trial for stenoparib in combination with temozolomide for the treatment of relapsed small cell lung cancer (SCLC), with the first patients already dosed [1][4]. Group 1: Clinical Trial Details - The trial is funded by the U.S. Department of Veterans Affairs (VA) and is being conducted across 11 VA medical centers in the United States [2][8]. - Patient recruitment is ongoing, reflecting a significant unmet medical need in relapsed SCLC [4][5]. Group 2: Mechanism of Action - Stenoparib is a dual inhibitor targeting both PARP and the WNT pathway, which may enhance the effects of temozolomide while mitigating drug resistance associated with advanced cancers like relapsed SCLC [3][4]. - The drug's ability to cross the blood-brain barrier is particularly relevant for SCLC, where brain metastases are common [6]. Group 3: Safety and Efficacy - Stenoparib has shown a favorable safety profile compared to earlier-generation PARP inhibitors, which were limited by hematologic toxicity [4]. - The combination therapy aims to maximize tumor cell death while minimizing toxicity risks [4]. Group 4: Market Context - Over 218,000 Americans are diagnosed with lung cancer annually, with approximately 12% being SCLC, highlighting the need for effective treatment options [5]. - Real-world data indicates that only 40% of SCLC patients receive second-line treatment, with a median treatment duration of under two months [5]. Group 5: Company Overview - Allarity Therapeutics is focused on developing personalized cancer treatments, particularly stenoparib, and utilizes a drug response predictor (DRP) to identify patients likely to benefit from treatment [11]. - The company has exclusive global rights for the development and commercialization of stenoparib, which was originally developed by Eisai Co. Ltd. [7].

Unnatural Products, Novartis sign license deal worth up to $1.7 billion for cardiovascular program | ReutersSkip to main content[Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv]A sign marks the Novartis Institutes for BioMedical Research facility in Cambridge, Massachusetts, U.S., June 16, 2021. REUTERS/Brian Snyder [Purchase Licensing Rights, opens new tab]- Companies[Novartis]FollowFeb 18 (Reuters) - Unnatural Products said on Wednesday it has signed a licens ...

BOCA RATON, Fla., Feb. 18, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT), a clinical stage pharmaceutical and med-tech company focused on advancing cancer treatments, today announced it has appointed Sidney Braun as Chief Executive Officer of the Company’s Liora Technologies Europe Ltd. subsidiary (“Liora”). A veteran of the healthcare industry, Braun brings to Liora more than two decades of operational and strategic advisory experience at companies in ...